Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients

Michael Mahler, Eric L Greidinger, M. Szmyrka, A. Kromminga, M. J. Fritzler

Research output: Chapter in Book/Report/Conference proceedingConference contribution

3 Citations (Scopus)

Abstract

Antibodies to double-stranded desoxyribonucleic acid (ds-DNA) and to the polymyositis/scleroderma (PM/Scl) complex are regarded as serological markers for systemic lupus erythematosus (SLE) and PM/Scl overlap syndrome, respectively. In a previous study, serum samples were identified that contained antibodies specific for both ds-DNA and PM/Scl. Fourteen of these sera were available for more detailed investigation including the autoantibody profile as determined by several methods including an addressable laser bead assay, Crithidia luciliae indirect immunofluorescence test (CLIFT) and a PM1-Alpha ELISA. Moreover, 300 samples from connective tissue disease patients and 30 PM/Scl positive samples were screened for anti-dsDNA+/PM/Scl + specimens by CLIFT, dsDNA ELISA, and PM1-Alpha ELISA. We confirmed anti-dsDNA and anti-PM/Scl reactivity in 2/7 samples from the previous study. One sample had also anti-chromatin and anti-SS-A reactivity and the second sample was oligoreactive. In addition, 2/300 (0.7%) unselected samples from connective tissue disease patients were identified with anti-dsDNA and anti-PM/Scl reactivity. In a panel of PM1-Alpha positive samples (n = 30) collected regardless of the diagnosis of the patients, no anti-dsDNA reactivity was found. All anti-dsDNA+/anti-PM/Scl+ patients identified fulfilled sufficient criteria to be classified as definite SLE and also had at least one feature of systemic sclerosis (i.e., sclerodactyly and/or Raynaud's phenomenon). Only 1/4 patients had clinical evidence of dermatomyositis. The combination of anti-dsDNA+/anti-PM/Scl + in patients suffering from connective tissue disease is less frequently found than previously described when newer assays are used. Clinically, anti-dsDNA+/anti-PM/Scl+ patients may define a small subgroup of SLE patients with additional features of systemic sclerosis.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages311-321
Number of pages11
Volume1109
DOIs
StatePublished - Aug 1 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1109
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Polymyositis
Tissue
Assays
Acids
Antibodies
Connective Tissue Diseases
Autoantibodies
Crithidia
Chromatin
Systemic Lupus Erythematosus
Systemic Scleroderma
Enzyme-Linked Immunosorbent Assay
Indirect Fluorescent Antibody Technique
Lasers
Raynaud Disease
Dermatomyositis
Serum

Keywords

  • Autoantibody
  • dsDNA
  • Peptide
  • PM/Scl
  • SLE

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mahler, M., Greidinger, E. L., Szmyrka, M., Kromminga, A., & Fritzler, M. J. (2007). Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients. In Annals of the New York Academy of Sciences (Vol. 1109, pp. 311-321). (Annals of the New York Academy of Sciences; Vol. 1109). https://doi.org/10.1196/annals.1398.037

Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients. / Mahler, Michael; Greidinger, Eric L; Szmyrka, M.; Kromminga, A.; Fritzler, M. J.

Annals of the New York Academy of Sciences. Vol. 1109 2007. p. 311-321 (Annals of the New York Academy of Sciences; Vol. 1109).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Mahler, M, Greidinger, EL, Szmyrka, M, Kromminga, A & Fritzler, MJ 2007, Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients. in Annals of the New York Academy of Sciences. vol. 1109, Annals of the New York Academy of Sciences, vol. 1109, pp. 311-321. https://doi.org/10.1196/annals.1398.037
Mahler M, Greidinger EL, Szmyrka M, Kromminga A, Fritzler MJ. Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients. In Annals of the New York Academy of Sciences. Vol. 1109. 2007. p. 311-321. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1398.037
Mahler, Michael ; Greidinger, Eric L ; Szmyrka, M. ; Kromminga, A. ; Fritzler, M. J. / Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients. Annals of the New York Academy of Sciences. Vol. 1109 2007. pp. 311-321 (Annals of the New York Academy of Sciences).
@inproceedings{19cf11b08dad4cdd8d4ca00ca21b5403,
title = "Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients",
abstract = "Antibodies to double-stranded desoxyribonucleic acid (ds-DNA) and to the polymyositis/scleroderma (PM/Scl) complex are regarded as serological markers for systemic lupus erythematosus (SLE) and PM/Scl overlap syndrome, respectively. In a previous study, serum samples were identified that contained antibodies specific for both ds-DNA and PM/Scl. Fourteen of these sera were available for more detailed investigation including the autoantibody profile as determined by several methods including an addressable laser bead assay, Crithidia luciliae indirect immunofluorescence test (CLIFT) and a PM1-Alpha ELISA. Moreover, 300 samples from connective tissue disease patients and 30 PM/Scl positive samples were screened for anti-dsDNA+/PM/Scl + specimens by CLIFT, dsDNA ELISA, and PM1-Alpha ELISA. We confirmed anti-dsDNA and anti-PM/Scl reactivity in 2/7 samples from the previous study. One sample had also anti-chromatin and anti-SS-A reactivity and the second sample was oligoreactive. In addition, 2/300 (0.7{\%}) unselected samples from connective tissue disease patients were identified with anti-dsDNA and anti-PM/Scl reactivity. In a panel of PM1-Alpha positive samples (n = 30) collected regardless of the diagnosis of the patients, no anti-dsDNA reactivity was found. All anti-dsDNA+/anti-PM/Scl+ patients identified fulfilled sufficient criteria to be classified as definite SLE and also had at least one feature of systemic sclerosis (i.e., sclerodactyly and/or Raynaud's phenomenon). Only 1/4 patients had clinical evidence of dermatomyositis. The combination of anti-dsDNA+/anti-PM/Scl + in patients suffering from connective tissue disease is less frequently found than previously described when newer assays are used. Clinically, anti-dsDNA+/anti-PM/Scl+ patients may define a small subgroup of SLE patients with additional features of systemic sclerosis.",
keywords = "Autoantibody, dsDNA, Peptide, PM/Scl, SLE",
author = "Michael Mahler and Greidinger, {Eric L} and M. Szmyrka and A. Kromminga and Fritzler, {M. J.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1196/annals.1398.037",
language = "English",
isbn = "1573316636",
volume = "1109",
series = "Annals of the New York Academy of Sciences",
pages = "311--321",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients

AU - Mahler, Michael

AU - Greidinger, Eric L

AU - Szmyrka, M.

AU - Kromminga, A.

AU - Fritzler, M. J.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Antibodies to double-stranded desoxyribonucleic acid (ds-DNA) and to the polymyositis/scleroderma (PM/Scl) complex are regarded as serological markers for systemic lupus erythematosus (SLE) and PM/Scl overlap syndrome, respectively. In a previous study, serum samples were identified that contained antibodies specific for both ds-DNA and PM/Scl. Fourteen of these sera were available for more detailed investigation including the autoantibody profile as determined by several methods including an addressable laser bead assay, Crithidia luciliae indirect immunofluorescence test (CLIFT) and a PM1-Alpha ELISA. Moreover, 300 samples from connective tissue disease patients and 30 PM/Scl positive samples were screened for anti-dsDNA+/PM/Scl + specimens by CLIFT, dsDNA ELISA, and PM1-Alpha ELISA. We confirmed anti-dsDNA and anti-PM/Scl reactivity in 2/7 samples from the previous study. One sample had also anti-chromatin and anti-SS-A reactivity and the second sample was oligoreactive. In addition, 2/300 (0.7%) unselected samples from connective tissue disease patients were identified with anti-dsDNA and anti-PM/Scl reactivity. In a panel of PM1-Alpha positive samples (n = 30) collected regardless of the diagnosis of the patients, no anti-dsDNA reactivity was found. All anti-dsDNA+/anti-PM/Scl+ patients identified fulfilled sufficient criteria to be classified as definite SLE and also had at least one feature of systemic sclerosis (i.e., sclerodactyly and/or Raynaud's phenomenon). Only 1/4 patients had clinical evidence of dermatomyositis. The combination of anti-dsDNA+/anti-PM/Scl + in patients suffering from connective tissue disease is less frequently found than previously described when newer assays are used. Clinically, anti-dsDNA+/anti-PM/Scl+ patients may define a small subgroup of SLE patients with additional features of systemic sclerosis.

AB - Antibodies to double-stranded desoxyribonucleic acid (ds-DNA) and to the polymyositis/scleroderma (PM/Scl) complex are regarded as serological markers for systemic lupus erythematosus (SLE) and PM/Scl overlap syndrome, respectively. In a previous study, serum samples were identified that contained antibodies specific for both ds-DNA and PM/Scl. Fourteen of these sera were available for more detailed investigation including the autoantibody profile as determined by several methods including an addressable laser bead assay, Crithidia luciliae indirect immunofluorescence test (CLIFT) and a PM1-Alpha ELISA. Moreover, 300 samples from connective tissue disease patients and 30 PM/Scl positive samples were screened for anti-dsDNA+/PM/Scl + specimens by CLIFT, dsDNA ELISA, and PM1-Alpha ELISA. We confirmed anti-dsDNA and anti-PM/Scl reactivity in 2/7 samples from the previous study. One sample had also anti-chromatin and anti-SS-A reactivity and the second sample was oligoreactive. In addition, 2/300 (0.7%) unselected samples from connective tissue disease patients were identified with anti-dsDNA and anti-PM/Scl reactivity. In a panel of PM1-Alpha positive samples (n = 30) collected regardless of the diagnosis of the patients, no anti-dsDNA reactivity was found. All anti-dsDNA+/anti-PM/Scl+ patients identified fulfilled sufficient criteria to be classified as definite SLE and also had at least one feature of systemic sclerosis (i.e., sclerodactyly and/or Raynaud's phenomenon). Only 1/4 patients had clinical evidence of dermatomyositis. The combination of anti-dsDNA+/anti-PM/Scl + in patients suffering from connective tissue disease is less frequently found than previously described when newer assays are used. Clinically, anti-dsDNA+/anti-PM/Scl+ patients may define a small subgroup of SLE patients with additional features of systemic sclerosis.

KW - Autoantibody

KW - dsDNA

KW - Peptide

KW - PM/Scl

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=34848884533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848884533&partnerID=8YFLogxK

U2 - 10.1196/annals.1398.037

DO - 10.1196/annals.1398.037

M3 - Conference contribution

C2 - 17785320

AN - SCOPUS:34848884533

SN - 1573316636

SN - 9781573316637

VL - 1109

T3 - Annals of the New York Academy of Sciences

SP - 311

EP - 321

BT - Annals of the New York Academy of Sciences

ER -